Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias

Bibliography

• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
   PubMed Web of Science ®Google Scholar
• MUGHAL TI, GOLDMAN JM: Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Front. Biosci. (2006) 11:198-208.
   Google Scholar
• QUINTAS-CARDAMA A, CORTES JE: Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin. Proc. (2006) 81(7):973-988.
   PubMed Web of Science ®Google Scholar
• FADERL S, KANTARJIAN HM, TALPAZ M: Chronic myelogenous leukemia: update on biology and treatment. Oncology (1999) 13(2):169-180.
   PubMed Web of Science ®Google Scholar
• BARNES DJ, MELO JV: Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol. (2002) 108(4):180-202.
   Google Scholar
• ROWLEY JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243(5405):290-293.
   PubMed Web of Science ®Google Scholar
• MARTINELLI G, SOVERINI S, ROSTI G, CILLONI D, BACCARANI M: New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica (2005) 90(4):534-541.
   PubMed Web of Science ®Google Scholar
• DEININGER M, BUCHDUNGER E, DRUKER BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2005) 105(7):2640-2653.
   PubMed Web of Science ®Google Scholar
• SCHINDLER T, BORNMANN W, PELLICENA P, MILLER WT, CLARKSON B, KURIYAN J: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289(5486):1938-1942.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, CIOFFI CL, LAW N et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. (2000) 295(1):139-145.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, CORTES J, O’BRIEN S et al.: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood (2002) 99(10):3547-3553.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, O’BRIEN S, CORTES JE et al.: Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood (2002) 100(5):1590-1595.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, SAWYERS C, HOCHHAUS A et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. (2002) 346(9):645-652.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, TALPAZ M, O’BRIEN S et al.: Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin. Cancer Res. (2002) 8(7):2177-2187.
   Google Scholar
• SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99(10):3530-3539.
   PubMed Web of Science ®Google Scholar
• TALPAZ M, SILVER RT, DRUKER BJ et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99(6):1928-1937.
   PubMed Web of Science ®Google Scholar
• O’BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348(11):994-1004.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, GUILHOT F, O’BRIEN S, LARSON RA: Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J. Clin. Oncol. (2006) 24(18S):338s (Abstract 6506).
   Google Scholar
• KERKELÄ R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.
   PubMed Web of Science ®Google Scholar
• LITZOW MR: Imatinib resistance: obstacles and opportunities. Arch. Pathol. Lab. Med. (2006) 130(5):669-679.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, LA ROSEE P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia (2004) 18(8):1321-1331.
   PubMed Web of Science ®Google Scholar
• LAHAYE T, RIEHM B, BERGER U et al.: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer (2005) 103(8):1659-1669.
   PubMed Web of Science ®Google Scholar
• NATIONAL COMPREHENSIVECANCER NETWORK: Clinical Practice Guidelines in Oncology – Chronic Myelogenous Leukemia (2007) version 1.
   Google Scholar
• GRATWOHL A: The role of allogeneic stem cell transplantation for chronic myeloid leukemia. Haematology Eur. Haematol. Assoc. Educ. Program (2006):98-102.
   Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293(5531):876-880.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, KREIL S, CORBIN AS et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 16(11):2190-2196.
   PubMed Web of Science ®Google Scholar
• ILLMER T, SCHAICH M, PLATZBECKER U et al.: P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia (2004) 18(3):401-408.
   PubMed Web of Science ®Google Scholar
• THOMAS J, WANG L, CLARK RE, PIRMOHAMED M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 104(12):3739-3745.
   PubMed Web of Science ®Google Scholar
• LARGHERO J, LEGUAY T, MOURAH S et al.: Relationship between elevated levels of the α1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem. Pharmacol. (2003) 66(10):1907-1913.
   Google Scholar
• LE COUTRE P, KREUZER KA, NA IK et al.: Determination of α-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol. Dis. (2002) 28(1):75-85.
   Google Scholar
• LIONBERGER JM, WILSON MB, SMITHGALL TE: Transformation of myeloid leukemia cells to cytokine independence by BCR-ABL is suppressed by kinase-defective Hck. J. Biol. Chem. (2000) 275(24):18581-18585.
   PubMed Web of Science ®Google Scholar
• DONATO NJ, WU JY, STAPLEY J et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 101(2):690-698.
   PubMed Web of Science ®Google Scholar
• DAI Y, RAHMANI M, COREY SJ, DENT P, GRANT S: A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem. (2004) 279(33):34227-34239.
   PubMed Web of Science ®Google Scholar
• DANHAUSER-RIEDL S, WARMUTH M, DRUKER BJ, EMMERICH B, HALLEK M: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. (1996) 56(15):3589-3596.
   PubMed Web of Science ®Google Scholar
• WARMUTH M, BERGMANN M, PRIESS A, HAUSLMANN K, EMMERICH B, HALLEK M: The Src family kinase Hck interacts with BCR-ABL by a kinase-dependent mechanism and phosphorlyates the Grb2-binding site of Bcr. J. Biol. Chem. (1997) 272(52):33260-33270.
   PubMed Web of Science ®Google Scholar
• ERNST TJ, SLATTERY KE, GRIFFIN JD: p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J. Biol. Chem. (1994) 269(8):5764-5769.
   PubMed Web of Science ®Google Scholar
• LIONBERGER JM, SMITHGALL TE: The c-FES protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukaemia cells induced by BCR-ABL. Cancer Res. (2000) 60(4):1097-1103.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, TALPAZ M, O’BRIEN S et al.: Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood (2003) 101(2):473-475.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, TALPAZ M, O’BRIEN S et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood (2004) 103(8):2873-2878.
   PubMed Web of Science ®Google Scholar
• SHAH NP: Loss of response to imatinib: mechanisms and management. Haematology Am. Soc. Haematol. Educ. Program (2005):183-187.
   Google Scholar
• LOMBARDO LJ, LEE FY, CHEN P et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. (2004) 47(27):6658-6661.
   PubMed Web of Science ®Google Scholar
• SCHITTENHELM MM, SHIRAGA S, SCHROEDER A et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. (2006) 66(1):473-481.
   PubMed Web of Science ®Google Scholar
• LEE FY, LOMBARDO L, CAMUSO A et al.: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc. Am. Assoc. Cancer. Res. (2005) 46:675 (Abstract).
   Google Scholar
• TOKARSKI JS, NEWITT JA, CHANG CY et al.: The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. (2006) 66(11):5790-5797.
   PubMed Web of Science ®Google Scholar
• SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305(5682):399-401.
   PubMed Web of Science ®Google Scholar
• O’HARE T, WALTERS DK, STOFFREGEN EP et al.: In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. (2005) 65(11):4500-4505.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL, SHAH NP, KANTARJIAN HM et al.: Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SCR/ABL kinase inhibitor BMS-354825: results from a Phase I dose escalation study. Blood (2004) 11:4 (Abstract 1).
   Web of Science ®Google Scholar
• TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354(24):2531-2541.
   PubMed Web of Science ®Google Scholar
• HOCHHAUS A, KANTARJIAN H, BACCARANI M et al.: Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 ‘START-C’ study. J. Clin. Oncol. (2006) 24(18S):339s (Abstract 6508).
   Google Scholar
• HOCHHAUS A, KANTARJIAN H, SHAH N et al.: A Phase II study of dasatinib in patients with chronic phase chronic myeloid leukemia who are resistant or intolerant to imatinib: results of the CA180013 START-C study. Haematologica (2006) 91(s1):170-171 Abstract 0467.
   Google Scholar
• TALPAZ M, APPERLEY JF, KIM DW et al.: Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: results of the CA180005 ‘START-A’ study. J. Clin. Oncol. (2006) 24(18S):343s (Abstract 6526).
   Google Scholar
• GUILHOT F, APPERLEY JF, HOCHHAUS A et al.: Dasatinib (D) in patients (pts) with accelerated phase chronic myeloid leukemia (AP-CML) resistant or intolerant to imatinib: results of the CA180005 ‘START-A’ study. Haematologica (2006) 91(s1):59 (Abstract 0159).
   Google Scholar
• CORTES JE, KIM DW, ROSTI G et al.: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 ‘START-B’ study. J. Clin. Oncol. (2006) 24(18S):344s (Abstract 6529).
   Google Scholar
• BACCARANI M, CORTES J, KIM DW et al.: Dasatinib in patient with chronic myelogenous leukemia in myeloid blast crisis (MBC) that is imatinib-resistant or IM-intolerant: results of the CA180006 START-B study. Haematologica (2006) 91(s1):56 (Abstract 0150).
   PubMed Web of Science ®Google Scholar
• COUTRE S, MARTINELLI G, DOMBRET H et al.: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): the CA180015 ‘START-L’ study. J. Clin. Oncol. (2006) 24(18S):344s (Abstract 6528).
   Google Scholar
• OTTMANN O, MARTINELLI G, DOMBRET H et al.: Dasatinib in patients with chronic myelogenous leukemia in lymphoid blast crisis of Philadelphia chromosome positive acute lymphoblastic leukemia that is imatinib-resistant or intolerant: the CA180015 START-L study. Haematologica (2006) 91(s1):241 (Abstract 0653).
   Google Scholar
• QUINTAS-CARDAMA A, KANTARJIAN H, JONES D et al.: Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. J. Clin. Oncol. (2006) 24(18S):343s (Abstract 6525).
   Google Scholar
• QUINTÁS-CARDAMA A, KANTARJIAN H, MUNDEN R et al.: Pleural effusions and dasatinib therapy. ASHASH Meeting Blood (2006) 108:2164 (Abstract).
   Web of Science ®Google Scholar
• SHAH NP, ROUSSELOT P, PASQUINI R et al.: Dasatinib (D) versus high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. J. Clin. Oncol. (2006) 24(18S):338s (Abstract 6507).
   Google Scholar
• KANTARJIAN H, ROUSSELOT P, PASQUINI D et al.: A randomized study of dasatinib versus escalated dose of imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib: results of CA180017 START-R study. Haematologica (2006) 91(s1):170 (Abstract 0465).
   Google Scholar
• CORTES J, TALPAZ M, O’BRIEN S et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. (2005) 11(9):3425-3432.
   Google Scholar
• WANG L, PEARSON K, FERGUSON JE, CLARK RE: The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. (2003) 120(6):990-999.
   PubMed Web of Science ®Google Scholar
• BURGESS MR, SKAGGS BJ, SHAH NP et al.: Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA (2005) 102(9):3395-3400.
   PubMed Web of Science ®Google Scholar